1. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

CHO-K1 cell

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

9

Peptides

1

MCE Kits

3

Inhibitory Antibodies

2

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99870

    ASLAN004; CSL-334

    Interleukin Related Others
    Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells .
    Eblasakimab
  • HY-136895

    Prostaglandin Receptor Cancer
    AZ12672857 is an orally active inhibitor of EphB4 (IC50=1.3 nM) and Src kinases. AZ12672857 shows good inhibition of proliferation of c-Src transfected 3T3 cells (IC50=2 nM) as well as autophosphorylation of EphB4 in transfected CHO-K1 cells (IC50=9 nM) .
    AZ12672857
  • HY-108003

    Apelin Receptor (APJ) Cardiovascular Disease
    MM 07 is a biased apelin receptor agonist, with a KD of 300 nM in CHO-K1 cells and a KD of 172 nM in human heart.
    MM 07
  • HY-P990009

    NIS-793

    TGF-beta/Smad Cancer
    Nisevokitug (NIS-793) is a human, IgG2λ antibody targeting TGF-β (TGFB1/TGFB2). Nisevokitug is expressed by CHO-K1 cells .
    Nisevokitug
  • HY-100962A

    Tyrphostin 46; Tyrphostin AG 99

    Tyrosinase Cancer
    AG 99 (Tyrphostin 46), a tyrphostin derivative, is a tyrosine kinase inhibitor that increases sister chromatid exchange frequency in transformed CHO-K1 and primary CHE cells. AG 99 is promising for research of proliferative diseases .
    AG 99
  • HY-P99888

    EGFR Others
    Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .
    Pimurutamab
  • HY-124104

    Drug Metabolite Cardiovascular Disease Metabolic Disease
    Aldicarb sulfoxide is a metabolite of Aldicarb. Aldicarb sulfoxide affects the glutathione-linked enzymes in CHO-K1 cells. Aldicarb sulfoxide inhibits cholinesterase (ChE) and carboxylesterase (CaE) with IC50 of 10 μM for both in zebrafish .
    Aldicarb sulfoxide
  • HY-P5872

    JZTX-XI

    Sodium Channel Neurological Disease
    Jingzhaotoxin XI (JZTX-XI) is a sodium conductance inhibitor with an IC50 of 124 nM. Jingzhaotoxin XI slows the fast inactivation (EC50=1.18±0.2 μM) of Nav1.5 expressed in Chinese hamster ovary (CHO-K1) cells .
    Jingzhaotoxin XI
  • HY-123335

    Somatostatin Receptor Others
    L-796,778 is an agonist of the hsst3 receptor. In CHO-K1 cells expressing the hsst3 receptor, L-796,778 is a partial agonist that inhibits forskolin (HY-15371)-stimulated cAMP production with an IC50 value of 18 nM .
    L-796,778
  • HY-117617

    Histone Acetyltransferase Cancer
    CAY10669 (compound 6d) is an anacardic acid (HY-N2020) derivative that inhibits histone acetyltransferase PCAF with an IC50 of 662 μM . CAY10669 enhances the SAHA-induced acetylation in HEPG2 cells, exhibits cytotoxicity in zebrafish embryo, promotes transgene expression in CHO-K1 cells .
    CAY10669
  • HY-124104S

    Isotope-Labeled Compounds Metabolic Disease
    Aldicarb sulfoxide-d3 is the deuterium labled Aldicarb sulfoxide (HY-124104). Aldicarb sulfoxide is a metabolite of Aldicarb. Aldicarb sulfoxide affects the glutathione-linked enzymes in CHO-K1 cells. Aldicarb sulfoxide inhibits cholinesterase (ChE) and carboxylesterase (CaE) with IC50 of 10 μM for both in zebrafish .
    Aldicarb sulfoxide-d3
  • HY-106423A

    CI-980; NSC 613862 isethionate; (S)-(-)-NSC 613862 isethionate

    Antifolate Microtubule/Tubulin Cancer
    Mivobulin (isethionate) (CI-980) is an orally active, brain-penetrant and potent folate antagonist and a tubulin-binding mitotic inhibitor. Mivobulin (isethionate) accumulates rapidly in L1210 and CHO/K1 cells to levels many-fold higher than those in the extracellular medium and efflux is also quite rapid. Mivobulin (isethionate) is promising for research of cancers .
    Mivobulin isethionate
  • HY-161247

    5-HT Receptor Metabolic Disease
    5HT2A antagonist 2 is an orally active, selective antagonist for 5HT2A with IC50 of 14 nM. 5-HT2A antagonist 2 exhibits good chemical, hepatocyte, and plasma stability, without significant cytotoxicity in cell lines VERO, HFL-1, L929, NIH3T3, CHO-K1 .
    5-HT2A antagonist 2
  • HY-P4146

    BI 456906

    GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide
  • HY-P4146A

    BI 456906 TFA

    GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide TFA
  • HY-113513

    Others Cancer
    5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.
    5-HEPE
  • HY-132225

    5-HT Receptor Inflammation/Immunology
    SB 206553 is a 5-HT2C inverse agonist. SB 206553 can attenuate methamphetamine-seeking in rats. SB 206553 has activity for 5-HT2 receptor ligands in HEK-293 or CHO-K1 cells expressing human recombinant 5-HT2 receptors with pKi values of 5.6 nM (5-HT2A), 7.7 nM (5-HT2B) and 7.8 nM (5-HT2C), respectively. SB 206553 can be used for the research of psychostimulant abuse disorders .
    SB 206553
  • HY-103120

    5-HT Receptor Neurological Disease
    Org37684 is a highly potent 5-HT2C receptor agonist (pEC50=8.17). Org37684 exhibits a rank order of potency of 5-HT2C>5-HT2B>5-HT2A. Its selectivity for the 5-HT2C receptor is approximately 2.5 times over the 5-HT2B (pEC50=7.96) and ten times for the 5-HT2A (pEC50=7.11) receptor .
    Org37684
  • HY-112469

    ERK Insulin Receptor Metabolic Disease
    ERK Inhibitor II (Negative control) is an effective inhibitor of extracellular signal-regulated kinase (ERK). ERK Inhibitor II (Negative control) inhibits the activation of insulin receptor, which can be used in the study of diabetes .
    ERK Inhibitor II (Negative control)
  • HY-P10378

    GnRH Receptor Metabolic Disease
    GPR10 agonist 1 (compound 18-S4) is a potent GPR10 agonist with EC50 values of 80, 7.8 nM in the presence (10%) or absence (0%) of FBS, respectively. GPR10 agonist 1 has the potential for the research of chronic obesity .
    GPR10 agonist 1
  • HY-155553

    GPR119 Metabolic Disease
    GPR119 agonist 2 (compound 43) is an orally active GPR119 agonist. GPR119 agonist 2 shows good pharmacokinetic characteristics in rodents and can effectively improve glucose tolerance in mice and rats. GPR119 agonist 2 has the potential to study type 2 diabetes .
    GPR119 agonist 2
  • HY-19443

    Histamine Receptor Lipoxygenase Inflammation/Immunology
    UCB-35440 is an orally active histamine H1 receptor antagonist and 5-lipoxygenase inhibitor. UCB-35440 inhibits LTB4 formation in human whole blood and reduces polymorphonuclear cell infiltration in mouse models. UCB-35440 inhibits histamine-stimulated bronchoconstriction and reduces skin inflammation in guinea pigs. UCB-35440 can be used for research on asthma and skin inflammation .
    UCB-35440
  • HY-162356

    PD-1/PD-L1 Cancer
    PD-L1-IN-4 (Compound X18) is an orally active PD-L1 inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC50 = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC50 = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer .
    PD-L1-IN-4
  • HY-P1185

    Vasopressin Receptor Apoptosis Cancer
    Antagonist G is a potent vasopressin antagonist. Antagonist G is also a weak antagonist of GRP and Bradykinin. Antagonist G induces AP-1 transcription and sensitizes cells to chemotherapy .
    Antagonist G
  • HY-P1185A

    Vasopressin Receptor Apoptosis Cancer
    Antagonist G TFA is a potent vasopressin antagonist. Antagonist G is also a weak antagonist of GRP and Bradykinin. Antagonist G induces AP-1 transcription and sensitizes cells to chemotherapy .
    Antagonist G TFA
  • HY-P2385

    Amino Acid Derivatives Others
    Fmoc-Val-Ser(psi(Me,Me)pro)-OH is a dipeptide.
    Fmoc-Val-Ser(psi(Me,Me)pro)-OH
  • HY-14840A

    MRZ 9547

    Dopamine Transporter Neurological Disease Inflammation/Immunology
    (R)-Phenylpiracetam (MRZ 9547) is a dopamine transporter (DAT) inhibitor (Ki: 14.8 μM; IC50: 65.5 μM). (R)-Phenylpiracetam can be used for the research of the neurological or neuropsychiatric disorders .
    (R)-Phenylpiracetam
  • HY-151884

    c-Myc Cancer
    FUBP1-IN-2 (compound 9) is a potent FUBP1 (far upstream binding protein 1) inhibitor. FUBP1-IN-2 inhibits the KH4 FUBP1-FUSE interaction in a gel shift assay. FUBP1-IN-2 binds to FUBP1 in a ChIP assay. FUBP1-IN-2 reduces both c-Myc mRNA and protein expression, increases p21 mRNA and protein expression, and depletes intracellular polyamines .
    FUBP1-IN-2
  • HY-W020790

    sLeX

    Endogenous Metabolite Inflammation/Immunology
    Sialyl-Lewis X (sLeX) is a sialylated fucosylated tetrasaccharide, an endogenous antigen. Sialyl-Lewis X is a high-affinity ligand for selectins (E-, P-, and L-selectin) . Sialyl-Lewis X binds to ELAM-1 and CD62 and has the ability?to inhibits CD62-mediated neutrophil recruitment to sites of inflammation .
    Sialyl-Lewis X

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: